E13.3411

Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

Risk-adjusting (HCC)Billable code

HCC risk adjustment mapping

CMS-HCC V28

HCC37

Diabetes with Chronic Complications

HCC298

Severe Diabetic Eye Disease, Retinal Vein Occlusion, and Vitreous Hemorrhage

CMS-HCC ESRD V24

HCC18

Diabetes with Chronic Complications

RxHCC V08

RXHCC30

Diabetes with Complications

Coding notes

Excludes 1 never coded together · Excludes 2 may co-exist

Inherited from E13.34Oth diabetes w severe nonproliferative diabetic retinopathy
7th character

One of the following 7th characters is to be assigned to codes in subcategory E13.34 to designate laterality of the disease:

Valid 7th characters and their meanings
CharacterMeaning
1right eye
2left eye
3bilateral
9unspecified eye
Inherited from E13Other specified diabetes mellitus
Includes

diabetes mellitus due to genetic defects of beta-cell function diabetes mellitus due to genetic defects in insulin action postpancreatectomy diabetes mellitus postprocedural diabetes mellitus secondary diabetes mellitus NEC

Excludes 1

diabetes (mellitus) due to autoimmune process (E10.-) diabetes (mellitus) due to immune mediated pancreatic islet beta-cell destruction (E10.-) diabetes mellitus due to underlying condition (E08.-) drug or chemical induced diabetes mellitus (E09.-) gestational diabetes (O24.4-) neonatal diabetes mellitus (P70.2) type 1 diabetes mellitus (E10.-)

Use additional

code to identify control using: injectable non-insulin antidiabetic drugs (Z79.85) insulin (Z79.4) oral antidiabetic drugs (Z79.84) oral hypoglycemic drugs (Z79.84)

Inherited from chapter 4Endocrine, nutritional and metabolic diseases
Excludes 1

transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Note

All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Official Guidelines for E13.3411

FY 2026 ›